ALK-Abelló news

Latest news

• 
  ALK-Abelló Pharmaceuticals Inc Announces Positive Funding Recommendation from Canada's Drug Agency for neffy® for the Emergency Treatment of Allergic Reactions (Anaphylaxis) (opens in a new tab)

  Oct 1, 2026

• ALK expands strategic tablet supply partnership with Catalent (opens in a new tab)

  Sep 30, 2026

• Why ALK-Abelló (CPSE:ALK B) Is Getting Attention Today (opens in a new tab)

  Sep 23, 2026

• 
  ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (opens in a new tab)

  Sep 21, 2026

• ALK to present at the Morgan Stanley Global Healthcare Conference in New York (opens in a new tab)

  Sep 11, 2026

• Alk-Abello AS (AKBLF) (Q2 2026) Earnings Call Highlights: Strong Tablet Sales and Raised ... (opens in a new tab)

  Aug 20, 2026

• ALK appoints Jacob Glenting as head of Global R&D (opens in a new tab)

  Aug 20, 2026

• Six-month interim report (Q2) 2026 (unaudited) (opens in a new tab)

  Aug 20, 2026

• ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system (opens in a new tab)

  Aug 14, 2026

• Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026 (opens in a new tab)

  Aug 13, 2026

• Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada (opens in a new tab)

  Aug 5, 2026

• Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight (opens in a new tab)

  Jul 27, 2026

• Is It Too Late To Consider ALK-Abelló (CPSE:ALK B) After Strong Multi‑Year Gains? (opens in a new tab)

  Jun 5, 2026

• ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026 (opens in a new tab)

  Jun 4, 2026

• ALK to present at the Jefferies Global Healthcare Conference in New York (opens in a new tab)

  May 29, 2026

• Three-month interim report (Q1) 2026 (unaudited) (opens in a new tab)

  May 4, 2026

• ALK upgrades its full-year outlook (opens in a new tab)

  May 4, 2026

• Assessing ALK Abelló (CPSE:ALK B) Valuation After Strong Recent Share Price Momentum (opens in a new tab)

  May 2, 2026

• Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026 (opens in a new tab)

  Apr 28, 2026

• Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff (opens in a new tab)

  Apr 8, 2026